Adar1 Capital Management, Llc Buys 35,101 Shares of Rallybio (NASDAQ:RLYB) Stock

Rallybio Corporation (NASDAQ:RLYB) major shareholder Adar1 Capital Management, Llc purchased 35,101 shares of Rallybio stock in a transaction that occurred on Tuesday, May 5th. The stock was acquired at an average price of $14.00 per share, with a total value of $491,414.00. Following the transaction, the insider owned 779,784 shares in the company, valued at $10,916,976. The trade was a 4.71% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Monday, May 4th, Adar1 Capital Management, Llc purchased 120,804 shares of Rallybio stock. The stock was acquired at an average price of $13.97 per share, with a total value of $1,687,631.88.

Rallybio Trading Up 2.0%

RLYB stock traded up $0.28 on Wednesday, hitting $14.56. The company’s stock had a trading volume of 238,233 shares, compared to its average volume of 611,199. The firm has a 50 day moving average of $9.01 and a two-hundred day moving average of $6.58. Rallybio Corporation has a 1 year low of $2.16 and a 1 year high of $15.31. The stock has a market cap of $77.02 million, a price-to-earnings ratio of -5.69 and a beta of -1.10.

Rallybio (NASDAQ:RLYB) last released its quarterly earnings results on Monday, March 16th. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.01. Rallybio had a negative net margin of 1,046.39% and a negative return on equity of 56.93%. The firm had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.10 million.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Rallybio to a “hold” rating in a research report on Saturday, March 28th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Institutional Investors Weigh In On Rallybio

A number of large investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC boosted its stake in shares of Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after purchasing an additional 373,821 shares during the last quarter. Susquehanna International Group LLP lifted its holdings in shares of Rallybio by 485.9% during the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after acquiring an additional 113,031 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Rallybio by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after acquiring an additional 2,996 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after acquiring an additional 120,892 shares during the period. Finally, XTX Topco Ltd lifted its holdings in shares of Rallybio by 64.6% during the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after acquiring an additional 38,205 shares during the period. 90.34% of the stock is owned by institutional investors and hedge funds.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.